Healthcare Fraud: Novo Nordisk Inc. Agrees to Pay to Resolve Allegations That The Company Failed to Comply For Its Type II Diabetes Medication

Healthcare Fraud: Novo Nordisk Inc. Agrees to Pay to Resolve Allegations That The Company Failed to Comply For Its Type II Diabetes Medication

Novo Nordisk Agrees to Pay $58 Million For Failure to Comply With FDA-Mandated Risk Program


Advertisements

Be the first to comment

Leave a Reply

Your email address will not be published.


*